Go to Page # Page of 17

Bevacizumab in Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

 R.A. Burger, M.F. Brady, M.A. Bookman, J.L. Walker, H.D. Homesley, J. Fowler, B.J. Monk, B.E. Greer,
Description: A Background information on Bevacizumab, Advanced Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer, Gynecologic Oncology Group (GOG) Study which will give you idea on GOG-0218, Ovarian cancer, epithelial ovarian [OV], primary peritoneal [PP], fallopian tube [FT] cancers, Vascular endothelial growth factor (VEGF), Bevacizumab (BEV), monoclonal antibody to VEGF, GOG-0218: Schema, Histologic diagnosis of epithelial OV, PP, or FT cancer.
Views: 2580
Domain: Medical
Category: Biotech/Pharma
weSRCH App on Apple
Phase III Trial of Bevacizumab in the Primary p , y Treatment of Advanced Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer: A Gynecologic Oncology Group (GOG) Study
R.A. Burger,1 M.F. Brady,2 M.A. Bookman,3 J.L. Walker,4 H.D. Homesley,5 J. Fowler, B.J. Monk, B.E. Greer, M. Boente S.X. J Fowler 6 B J Monk 7 B E Greer 8 M Boente,9 S X Liang10
Chase Cancer Center, Philadelphia, PA; 2G ... See more

Recent Presentations

22 July, 2019
Tine Peeters
21 July, 2019

FDA's Approach to the Opioids Crisis

FDA is working in a prioritized way in multiple areas to confront opioid overdoses while working to ensure patients receive appropriate pain treatment.

20 July, 2019